Changeflow GovPing Pharma & Drug Safety Monoclonal Antibody Specifically Binding CD20 -...
Routine Notice Added Final

Monoclonal Antibody Specifically Binding CD20 - Biocad Patent

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published Patent EP3875486A1 for a monoclonal antibody specifically binding to CD20, filed by Russian biotech company Biocad. The patent covers therapeutic applications including cancer treatments (A61P 35/00, A61P 35/02) and immune disorders (A61P 37/02). The designation extends across 38 European states including DE, FR, GB, IT, ES, NL, and others.

What changed

EPO granted Patent EP3875486A1 to Joint Stock Company Biocad for a monoclonal antibody that specifically binds to CD20. The patent application covers therapeutic uses in oncology (lymphoma, leukemia) and immunological disorders. Inventors include 19 named researchers led by Iakovev and Pestova. IPC classifications span C07K 16/28 (antibodies), C12N 5/10 (host cells), and multiple pharmaceutical applications.

Patent publication does not create immediate compliance obligations for third parties. Competitors developing CD20-targeted therapies should review the patent claims for potential freedom-to-operate concerns. Generic or biosimilar developers should assess design-around options before proceeding with R&D investments in this antibody space.

Source document (simplified)

← EPO Patent Bulletin

MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20

Publication EP3875486A1 Kind: A1 Mar 25, 2026

Applicants

Joint Stock Company "Biocad"

Inventors

IAKOVLEV, Pavel Andreevich, PESTOVA, Natalia Eugenievna, ANIKINA, Arina Vitalevna, TRUDOVISHNIKOVA, Anna Alexandrovna, SHCHEMELEVA, Mariia Aleksandrovna, KHARATIAN, Nina Grachyaevna, SOLOVYEV, Valery Vladimirovich, MISORIN, Alexey Konstantinovich, DIDUK, Sergei Vasilyevich, EROSHOVA, Anna Vladimirovna, USATOVA, Veronika Sergeevna, KRENDELEVA, Elena Andreevna, USTIUGOV, Iakov Iurevich, ALEKSANDROV, Aleksei Aleksandrovich, SMIRNOVA, Iana Andreevna, KOSKOVA, Svetlana Vladimirovna, IVANOV, Roman Alekseevich, MOROZOV, Dmitry Valentinovich

IPC Classifications

C07K 16/28 20060101AFI20220627BHEP C12N 5/10 20060101ALI20220627BHEP C12N 15/13 20060101ALI20220627BHEP C12N 15/63 20060101ALI20220627BHEP C12P 21/08 20060101ALI20220627BHEP A61K 39/395 20060101ALI20220627BHEP A61P 35/00 20060101ALI20220627BHEP A61P 35/02 20060101ALI20220627BHEP A61P 37/02 20060101ALI20220627BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

C07K 16/28 - Antibodies C12N 5/10 - Host Cells A61K 39/395 - Pharmaceutical Preparations A61P 35/00 - Antineoplastic Agents

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3875486A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 3345 Medical Device Manufacturing
Activity scope
Biopharmaceutical Patent Therapeutic Antibody Development
Geographic scope
Germany DE

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.